Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug clearance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,062 result(s) found for: Drug clearance. Displaying page 14 of 104.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    EudraCT Number: 2020-001430-35 Sponsor Protocol Number: 35RC19_8860_FLUDROSEPSIS Start Date*: 2021-04-21
    Sponsor Name:CHU Rennes
    Full Title: Evaluation of the hemodynamic effects of fludrocortisone on the pressive response to norepinephrine in patients in septic shock
    Medical condition: septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003533-15 Sponsor Protocol Number: LIFE-04-CHF Start Date*: 2018-12-04
    Sponsor Name:Department of Cardiology, Aarhus University Hospital
    Full Title: Clinical and pathophysiological aspects of visualization of metabolic flux in the failing human heart using hyperpolarized [1-13C]-pyruvate cardiac magnetic resonance
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10007540 Cardiac disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003283-10 Sponsor Protocol Number: BRAF01 Start Date*: 2020-11-11
    Sponsor Name:Camilla Qvortrup
    Full Title: BEACON regimen with cetuximab every second week - Cetuximab given every second week with encorafenib in pre-treated patients with BRAFV600E mutated metastatic colorectal cancer. A phase II study.
    Medical condition: Pre-treated BRAFV600E metastatic colorectal adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005596-40 Sponsor Protocol Number: SFT-AX2014 Start Date*: 2014-03-14
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor
    Medical condition: Advanced solitary fibrous tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014456-29 Sponsor Protocol Number: Cord01 Start Date*: 2009-09-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA
    Medical condition: Advanced chordoma EGFR/Her2Neu positive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039492 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000326-54 Sponsor Protocol Number: C16014 Start Date*: 2013-10-08
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Dia...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000091-24 Sponsor Protocol Number: TAK-442 202 Start Date*: 2008-12-02
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
    Medical condition: acute coronary syndromes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) EE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-000528-39 Sponsor Protocol Number: TAK-676-1002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc. (TDC Americas)
    Full Title: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Ad...
    Medical condition: Solid Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005576-26 Sponsor Protocol Number: 08-PIR-04 Start Date*: 2009-02-19
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable L...
    Medical condition: Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008606-52 Sponsor Protocol Number: EMN01 Start Date*: 2009-03-26
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: A PHASE 3, INTERGROUP MULTICENTRE, RANDOMIZED, CONTROLLED 3 ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE (Rd) VERSUS MELPHALAN, PR...
    Medical condition: MULTIPLE MYELOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-001111-36 Sponsor Protocol Number: CAN04CLIN001 Start Date*: 2018-01-25
    Sponsor Name:Cantargia AB
    Full Title: An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
    Medical condition: Solid malignant tumors, in the following two indications; Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC),
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) DK (Completed) NL (Completed) DE (Completed) AT (Completed) EE (Completed) ES (Ongoing) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005510-34 Sponsor Protocol Number: MMV_DSM265_14_01 Start Date*: 2015-09-30
    Sponsor Name:Medicines for Malaria Venture
    Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge
    Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10025494 Malaria prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004695-20 Sponsor Protocol Number: ML19313 Start Date*: 2006-03-27
    Sponsor Name:Roche Pharma AG
    Full Title: Randomized multicenter trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteration
    Medical condition: Prevention of cytomegalovirus (CMV) disease in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015817-31 Sponsor Protocol Number: OC3-DB-02 Start Date*: 2009-12-01
    Sponsor Name:OxThera IP AB
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004859-32 Sponsor Protocol Number: TTD-20-04 Start Date*: Information not available in EudraCT
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations
    Medical condition: Metastatic pancreatic cancer and DNA Damage Repair genes alterations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004170-26 Sponsor Protocol Number: APHP190205 Start Date*: 2021-04-08
    Sponsor Name:Assistance-Publique - Hôpitaux de Paris
    Full Title: PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION PCL-2 Study
    Medical condition: PRIMARY PLASMA CELL LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023783-41 Sponsor Protocol Number: E7080-G000-303 Start Date*: 2011-07-05
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I- Refractory Differentiated Thyroid Cancer
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) DK (Completed) AT (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003849-15 Sponsor Protocol Number: CT-P13_3.7 Start Date*: 2020-04-03
    Sponsor Name:Celltrion, Inc.
    Full Title: A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderat...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) BG (Completed) ES (Prematurely Ended) CZ (Completed) PL (Completed) GR (Prematurely Ended) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000201-69 Sponsor Protocol Number: D5290C00005 Start Date*: 2019-08-13
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-...
    Medical condition: The prevention of medically attended RSV LRTI.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) LV (Completed) GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) BG (Completed) CZ (Completed) EE (Completed) HU (Completed) LT (Completed) PL (Completed) FI (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005582-73 Sponsor Protocol Number: ACE-CL-007 Start Date*: 2015-07-03
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previ...
    Medical condition: Untreated Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:11:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA